Health

OpenAI lets clinicians prescribe from ChatGPT through Photon, moving pharmacy choice to patients

For Evidenced, the healthcare venture firm that bets on U.S. regulatory tailwinds, the launch adds a second engine: market-driven distribution through OpenAI's clinician base. The free window through December 31 is the first adoption test for its portfolio company Photon.

Richard TangRichard Tangthree-minute read
Share
Bryan Sivak speaking on a conference stage with a microphone, wearing a dark blazer over a light blue shirt.
Bryan Sivak, co-founder and managing partner of the healthcare venture firm Evidenced, speaking at a technology conference. Evidenced's portfolio company Photon Health went live inside ChatGPT on November 16.

Prescriptions can now start in the conversation instead of the medical record. On November 16, Photon Health, a Brooklyn e-prescribing startup founded in 2021, went live inside ChatGPT: a clinician names the patient and the drug, Photon drafts the prescription with interaction and allergy checks, the clinician verifies and signs, and the patient gets a text link to compare pharmacies on price, location and hours 12. Access is free at launch 1.

The signature stayed with the human

Clinicians set up a prescriber profile with their National Provider Identifier, complete clinician verification before signing, and must finish OpenAI's$1.18T — OpenAI, private, latest valuation $1.18T Business Associate Agreement, the HIPAA contract, before patient data flows 2. Drafts are screened for drug interactions and checked against the patient's recorded allergies and medications, and controlled substances are excluded 12. The responsibility sits with the signer: "You remain responsible for the treatment decision and the prescription you authorize," Photon's setup page tells clinicians 2.

"AI is quickly becoming where clinical decisions take shape, and the tools that support care should meet clinicians there," Photon chief executive Otto Sipe said 1. OpenAI's September connection to Epic, whose records cover more than 325 million patients, let ChatGPT read charts and write nothing back 6. Photon's plugin goes further and sends a signed prescription out of the conversation 4.

Routing is the part that moved

Photon runs its own prescription network rather than the legacy rails, so a patient who hits a closed pharmacy or an out-of-stock drug picks another through Photon without the clinician resending anything 12. The choice of pharmacy moves to the patient at the moment of prescribing, and every price-based choice pulls volume away from the default routing that pharmacy benefit managers and mail-order pharmacies rely on.

No volume data has been published yet, so that shift is a projection. The marketplace it would run through is already live in patients' text messages 2.

A regulation-first investor gets a market-driven channel

Evidenced, the healthcare venture firm co-founded by managing partners Bryan Sivak, who held executive roles at the Department of Health and Human Services and at Kaiser Permanente, and Sean Glass, invests in companies that benefit from U.S. regulatory tailwinds 3. Photon is one of 12 names on its portfolio page 3.

The reach into clinicians' hands came through OpenAI's product: the same-day healthcare expansion added more than 20 plugins and put Photon among them 45, and the publicly traded CVS Health−0.05% — CVS Health, down 0.05 percent today and Cigna−0.75% — Cigna, down 0.75 percent today are already deploying OpenAI's agents 5. ChatGPT for Clinicians is free for verified U.S. clinicians 2, which makes OpenAI's clinician base a distribution layer health investors now have to price.

What is left to prove is habit

The gap between a model that can draft a prescription and a clinician actually sending one was compliance plumbing and distribution, and Photon has now closed both 12.

If clinicians keep starting prescriptions in ChatGPT once the free period ends on December 31 2, OpenAI becomes the place prescribing begins and Photon carries every one of those orders to a pharmacy, a position EHR vendors hold today. The free window is where that gets decided. The sign to watch is clinicians returning on their own, week after week, to draft in the chat rather than opening the EHR.

Get Health by email, free

AI in medicine, pharma and biotech. In our daily email, every weekday.

Loading CVS

Reader comments

0 comments

    More in Health

    All in this topic →

    Health

    Kaiser's 1,200-scan trial found AI echo drafts matched clinicians and halved read time

    The Permanente Medical Group ran the randomized trial of EchoPrime itself and found the AI drafts matched clinician drafts while cutting cardiologist read time nearly in half. Days later it launched Permanentech, its own vehicle to commercialize clinical AI, so the buy-or-build question just got a benchmark.

    Health

    Eli Lilly Agreed to Buy Calytrix Bio for Up to $1.5 Billion, Its Latest Deal in a $32 Billion Year

    A $32 billion acquisition year rests on an $11 billion quarterly cash engine, but the deal headlines are "up to" figures and the balance sheet is already thinning. Whose money moves: anyone holding LLY at 31 times forward earnings into December 7 and January.

    Health

    GE HealthCare's manganese MRI agent matched gadolinium, a route past China's rare earths

    About 65 million contrast-enhanced MRI scans a year run on gadolinium, a rare earth whose export China licenses. A manganese substitute that matched the incumbent in GE HealthCare's Phase 2 trial opens a route off that chain for the company's highest-margin segment, if Phase 3 holds.

    Health

    Abridge lost AI scribing to Microsoft and Epic; its next market has a $100 million price from Wolters Kluwer

    Microsoft and Epic took two of every three new AI-scribe dollars this year, and Abridge, which built that market, is selling what comes after the note. The decision-support category it is moving into just got a public price, Wolters Kluwer's $100 million AgileMD deal, and that price is what Abridge's $6.69 billion private mark has to outrun.

    Health

    CMS's CRUSH rule reaches past Medicare into Molina's $42 billion Medicaid book

    The November 18 rout priced the proposal as a UnitedHealth-Humana Medicare bill. Molina is leaving that business, so for it the rule's weight falls on the Medicaid audit duties covering the $42 billion premium book that carries its $9.50 2027 earnings framework.

    Health

    AstraZeneca commits $200 million to Tempus AI through 2031 but can walk away for the shortfall

    A five-year, $200 million renewal from AstraZeneca gives Tempus AI a revenue floor it can book, filed days before a shareholder vote on a stock-funded acquisition, but the contract lets the drugmaker quit early by paying only the shortfall.

    Subscribe to TheInference for free